SQ-109

DB05186InvestigationalSmall molecule

SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line...

Mechanism: With a mechanism of action distinct from other antibiotics used in TB therapy, SQ109 inhibits cell wall synthesis and acts on multiple cellular pathways in a select group of microorganisms.
Curator reviewed
Primary indication: Investigated for use/treatment in bacterial infection, infectious and parasitic disease (unspecified), and tuberculosis.Curator reviewed
Formula / weight: C₂₂H₃₈N₂ · 330.5505 g/mol (avg)
Also known as: N-adamantanyl-N'-geranyl-ethylenediamine
Code names: SQ-109

Resolves to

Compound

UNII9AU7XUV31ACAS502487-67-4ChEMBLCHEMBL561057PubChem5274428

Structure

InChIKeyJFIBVDBTCDTBRH-REZTVBANSA-NSMILESCC(C)=CCC\C(C)=C\CNCCNC1C2CC3CC(C2)CC1C3

Targets

A9JQL9crtM

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with SQ-109, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account